Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Colorectal Neoplasms × Tablets × Clear all

Phase

Phase EARLY_PHASE1 1 Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Tracheal Diseases 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Small Cell Lung Carcinoma 1 Salivary Gland Neoplasms 1 Pancreatic Neoplasms 1 Neoplasm Metastasis 1 Mesothelioma 1 Lung Neoplasms 1 Laryngeal Diseases 1 Head and Neck Neoplasms 1 Glioblastoma 1 Esophageal Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Adenoid Cystic 1 Breast Neoplasms 1

Interventions

Cetuximab 39 Irinotecan 31 pembrolizumab 30 Capecitabine 30 Oxaliplatin 28 Bevacizumab 28 Fluorouracil 26 Leucovorin 24 Nivolumab 17 Gemcitabine 12 Cyclophosphamide 12 regorafenib 10 Folfox protocol 10 Pemetrexed 9 Cisplatin 9 Carboplatin 9 Paclitaxel 8 IFL protocol 8 tislelizumab 7 Panitumumab 7 130-nm albumin-bound paclitaxel 7 durvalumab 6 HMPL-013 6 Drug Therapy 6 irinotecan sucrosofate 5 Trifluridine 5 Specimen Handling 5 Ipilimumab 5 Docetaxel 5 trametinib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07435584 2026-02-27

EVER-RECODE

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 1/2 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡